Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

• Alejandro Martín, E. Gómez Conde, +16 authors M Erika Caballero
• Haematologica
• 2008

BACKGROUND The role of re-treatment with rituximab in aggressive B-cell lymphomas still needs to be defined. This study evaluated the influence of prior exposure to rituximab on response rates and… (More)

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

• David Martínez-Cuadrón, P Montesinos, +19 authors Miguel Angel Sanz
• Leukemia
• 2018

Treatment outcome in older patients with acute promyelocytic leukemia (APL) is lower compared with younger patients, mainly because of a higher induction death rate and postremission non-relapse… (More)

Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)

• Meritxell Nomdedeu, Xavier Calvo, +22 authors Arturo Pereira
• 2015

Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes

• Julia Montoro, Helena Pomares, +13 authors D Valcarcel
• Leukemia & lymphoma
• 2018

In clinical practice, patients with myelodysplastic syndromes (MDS) are usually classified in low or high-risk groups to take therapeutic decisions, conservative for low-risk, whereas active for… (More)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

• Blanca Xicoy, Ulrich Germing, +28 authors Guillermo Sanz
• European journal of haematology
• 2016

BACKGROUND The efficacy of erythropoietic-stimulating agents (ESA) in chronic myelomonocytic leukemia (CMML) is unknown. Our objective was to analyze erythroid response (ER) and overall survival (OS)… (More)

Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation

• Isabel Sánchez-Ortega, Beatriz Patińo, +5 authors R. Duarte
• Journal of medical economics
• 2013

PURPOSE To evaluate the cost-effectiveness of posaconazole vs itraconazole in the prevention of invasive fungal infections (IFIs) in recipients of allogeneic hematopoietic stem cell transplantation… (More)

• ‹
• 1
• ›